RTOG Foundation Study 3505

Status Date:  January 23, 2019  | Status:  Terminated

Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer

Principal Investigator

David E. Gerber, MD

Primary Objective

To compare the overall survival (OS) for patients with Stage III unresectable non-small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.

Patient Population

Patients with Stage IIIA or stage IIIB pathologically proven NSCLC with unresectable, medically inoperable disease, or patients who refuse resection.

Study Results

This study was terminated early due to the reporting of another study which changed this population's standard of care and rendered the control arm obsolete. Eight of the planned 550 analyzable participants were enrolled at the time of termination. No publication was generated for this study due to its early termination. Study results are posted on ClinicalTrials.gov.

Participating Sites

Institution Name City State/Country
Case Western Reserve University Cleveland OH
Cleveland Clinic Foundation Cleveland OH
Emory University/Winship Cancer Center Atlanta GA
Greater Baltimore Medical Center Baltimore MD
Henry Ford Hospital Detroit MI
Inova Fairfax Hospital Falls Church VA
Nancy N. & J.C. Lewis Research and Cancer Pavilion @St. Joseph’s/Candler Savannah GA
McGill University Department of Oncology Montreal QC
Memorial Sloan Kettering Cancer Center New York NY
Mercy Medical Center Baltimore MD
MetroHealth Medical Center Cleveland OH
Mount Sinai Medical Center Miami Beach FL
Reading Hospital West Reading PA
Stanford Cancer Institute Palo Alto CA
Toledo Cancer Center Toledo OH
UC San Diego Moores Cancer Center La Jolla CA
University of Florida Gainesville FL
University of Kentucky Lexington KY
University of Rochester Rochester NY
University of Wisconsin Hospital and Clinics Madison WI
UT-Southwestern Dallas TX
Virginia Mason Medical Center Seattle WA

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials